Advances in Lung Cancer Vol. 7 No. 4 |
|
- Newly Diagnosed, Advanced-Stage Non–Small-Cell Lung Cancer: Considerations for First-line Treatment
- Second- and Third-line Treatment Options for Advanced Non–Small-Cell Lung Cancer
- Agents Targeting Mammalian Target of Rapamycin and Heat Shock Protein 90 in Non–Small-Cell Lung Cancer
1 AMA PRA Category 1 CreditTM
Expiration date: January 17, 2009 |
Angiogenesis in Oncology Vol. 2, No. 6 |
|
- Current Status of Antiangiogenesis Therapy of Colorectal Cancer: Timing and Duration of Therapy
- Combined Modality Therapy in Early-Stage Non–Small-Cell Lung Cancer: The Potential and Future Role of Antiangiogenic Agents
- Targeting the Tumor Microenvironment
1 AMA PRA Category 1 CreditTM
Expiration date: January 17, 2009 |
Oncology Consultations Vol. 4, No. 10 |
|
- Q&A: Impact of Patient and Tumor Characteristics in Lung Adenocarcinoma
- SB 1: Second-Line Therapy for Advanced NSCLC
- SB 2: Impact of Smoking History on Therapy With EGFR TKIs in Lung Cancer
1 AMA PRA Category 1 CreditTM
Expiration date: December 22, 2008 |
Cancer
Abstracts & Summaries Vol. 8, No. 8 |
|
- Targeted Agents in NSCLC: Novel Agents, Novel Settings
- Phase III Trial of First-line Gemcitabine/Cisplatin/Bevacizucmab
in Advanced Nonsquamos NSCLC
- Phase III Trial of Gefitinib Compared
to Docetaxel in Patients With Previously Treated Advanced
NSCLC
- Phase II Trial of First-line Erlotinib
in Patients With Advanced or Metastatic NSCLC
- Phase II Trial of First-line XL647 in
Patients With NSCLC Enriched for Sensitivity
to EGFR Tyrosine Kinase Inhibitors
- Ongoing Phase II/III Trials of Antiangiogenic
Agents in NSCLC
1 AMA PRA Category 1 CreditTM
Expiration date: December 7, 2008 |
Targeted
Therapies and Evolving Treatment Paradigms for Lung
Cancer |
|
- Molecular Pathogenesis of NSCLC
- Individualizing Therapies in NSCLC Based on Tumor Biology and Patient Characteristics
- Optimizing the Use of EGFR Inhibitors
in Patients With NSCLC
- Integration of Antiangiogenesis Agents
Into Treatment Paradigms for NSCLC
- Quality of Life and Adverse Events Associated
With targeted Therapy in NSCLC
- New Therapeutic Agents for NSCLC
1 AMA PRA Category 1 CreditTM
Expiration date: December 7, 2008 |
Optimal
Application of Epidermal Growth Factor Receptor and Angiogenesis
Inhibitors in Lung Cancer |
|
- Targeting Angiogenesis in Non-Small-Cell
Lung Cancer
- Novel High-Affinity Vascular Endothelial
GrowthFactor/Multitargeted Tyrosine
Kinase Inhibitors
- Epidermal Growth Factor Receptor
Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer: Where Are
We in 2007?
- Overcoming Resistance to Epidermal
Growth Factor Receptor Tyrosine
Kinase Inhibitors
1 AMA PRA Category 1 CreditTM
Expiration date: November 30, 2008 |
| Advances in Lung Cancer Vol. 7, No. 3 |
|
- Response to TKIs Targeting EGFR
- Second-Generation EGFR TKIs
1 AMA PRA Category 1 Credit™
Expiration date: November 20, 2008
|
Emerging Pathways With Therapeutic Potential in Cancer |
|
- Targeting Signaling Pathways to Inhibit Cancer Growth
- Targeting the MAP/MEK and PI3K/Akt Pathways
- Novel Small-Molecular Inhibitors Targeting VEGFR in Breast Cancer
- Vaccines in Lung Cancer
- Novel Immunologic Targets in Metastatic Melanoma
- Combining Targeted Agents to Improve Therapeutic Efficacy
1 AMA PRA Category 1 CreditTM
Expiration date: November 20, 2008 |
| The Interface Between Molecular Biology and Clinical Practice: Targeting the Ras/Raf Signaling Network in Cancer |
|
- Efficacy of Biologic Targeted Agents in Hepatocellular Carcinoma
- Antiangiogenic Agents in NSCLC
- Beyond Proof of Principle for Multikinase Inhibitors in Renal Cell Carcinoma
- Update on Therapeutic Inhibition of Raf in Metastatic Melanoma
1 AMA PRA Category 1 Credit™
Expiration date: October 31, 2008
|
| Oncology Briefings Vol. 5, No. 7 |
|
- Advances in Chemotherapy for Metastatic NSCLC
1 AMA
PRA Category 1 Credit™
Expiration date: October 22, 2008
|
| Oncology Consultations Vol. 4, No. 6 |
|
- Treatment of a Patient With Metastatic Adenocarcinoma of the Lung
1 AMA
PRA Category 1 Credit™
Expiration date: October 15, 2008
|
| Cancer Abstracts & Summaries Vol. 8, No. 6 |
|
- Optimizing the Application of Targeted Agents in Non¨¢Small-Cell Lung Cancer
1 AMA
PRA Category 1 Credit™
Expiration date: September 30, 2008
|
